on November 7, 2005
Published online before print November 7, 2005, doi: 10.1161/CIRCULATIONAHA.104.526848
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on December 2, 2004
From the Department of Vascular Biochemistry (C.J.P., J.S.), Division of Cardiovascular and Medical Sciences (S.M.C., P.W.M.), and Department of Geriatric Medicine (D.J.S.), University of Glasgow, Glasgow, Scotland; Clinical Trials Unit (A.G.), North Glasgow Division, Greater Glasgow Health Board, Glasgow, Scotland; Robertson Centre for Biostatistics (I.F., M.R.), University of Glasgow, Glasgow, Scotland; Department of Pharmacology and Therapeutics (B.M.B., M.B.M.), Cork University Hospital, Wilton, Cork, Ireland; Department of Epidemiology and Public Health (I.J.P.), Departments of Geriatric Medicine (M.H., C.T.), and Department of Neurology (B.S.), Cork University Hospital, Wilton, Cork, Ireland; Section of Gerontology and Geriatrics (G.J.B., R.G.J., A.M.K.) and Departments of Cardiology (J.W.J.) and Neurology (E.L.E.M.), Leiden University Medical Centre, Leiden, The Netherlands. * To whom correspondence should be addressed. E-mail: chris.packard{at}clinmed.gla.ac.uk.
Background--Statins are important in vascular disease prevention in the elderly. However, the best method of selecting older patients for treatment is uncertain. We assessed the role of plasma lipoproteins as predictors of risk and of treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Method and Results--The association of LDLc and HDLc with risk was examined in the 5804 70- to 82-year-old subjects of PROSPER. Baseline LDLc showed no relation to risk of the primary end point in the placebo group (P=0.27), nor did on-treatment LDLc in the pravastatin group (P=0.12). HDLc was inversely associated with risk in subjects on placebo (P=0.0019) but not in those on pravastatin (P=0.24). Risk reduction on pravastatin treatment was unrelated to baseline LDLc (P=0.38) but exhibited a significant interaction with HDLc (P=0.012). Subjects in the lowest 2 quintiles of HDLc (<1.15 mmol/L) had a risk reduction of 33% (hazard ratio, 0.67; 95% confidence limits, 0.55, 0.81; P<0.0001), whereas those with higher HDLc showed no benefit (RR, 1.06; 95% confidence limits, 0.88, 1.27; P=0.53). During follow-up, there was no relation between achieved level of LDLc or HDLc and risk. However, the change in the LDLc/HDLc ratio on statin treatment appeared to account for the effects of therapy. Conclusions--In people >70 years old, HDLc appears to be a key predictor of risk and of treatment benefit. Findings in PROSPER suggest that statin therapy could usefully be targeted to those with HDLc <1.15 mmol/L or an LDLc/HDLc ratio >3.3.
Revised on August 17, 2005
Accepted on August 18, 2005
Plasma Lipoproteins and Apolipoproteins as Predictors of Cardiovascular Risk and Treatment Benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Chris J. Packard DSc*,
Key words: coronary disease • risk factors • cholesterol • drugs
This article has been cited by other articles:
 |
|
 |
|
  A. Murray, C. Cluett, S. Bandinelli, A. M. Corsi, L. Ferrucci, J. Guralnik, A. Singleton, T. Frayling, and D. Melzer Common lipid-altering gene variants are associated with therapeutic intervention thresholds of lipid levels in older people Eur. Heart J., July 2, 2009; 30(14): 1711 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus Conference Report From the American Diabetes Association and the American College of Cardiology Foundation J. Am. Coll. Cardiol., April 15, 2008; 51(15): 1512 - 1524. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brunzell, M. Davidson, C. D. Furberg, R. B. Goldberg, B. V. Howard, J. H. Stein, and J. L. Witztum Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care, April 1, 2008; 31(4): 811 - 822. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Fernandez and D. Webb The LDL to HDL Cholesterol Ratio as a Valuable Tool to Evaluate Coronary Heart Disease Risk J. Am. Coll. Nutr., February 1, 2008; 27(1): 1 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. P. Berbee, S. P. Mooijaart, A. J. M. de Craen, L. M. Havekes, D. van Heemst, P. C. N. Rensen, and R. G. J. Westendorp Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2008; 63(2): 122 - 126. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sattar, H. M. Murray, A. McConnachie, G. J. Blauw, E. L.E.M. Bollen, B. M. Buckley, S. M. Cobbe, I. Ford, A. Gaw, M. Hyland, et al. C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Circulation, February 27, 2007; 115(8): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Robinson, G. Bakris, J. Torner, N. J. Stone, and R. Wallace Is it Time for a Cardiovascular Primary Prevention Trial in the Elderly? Stroke, February 1, 2007; 38(2): 441 - 450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Do Low HDL Levels Predict Statin Benefits in the Elderly? Journal Watch Cardiology, December 9, 2005; 2005(1209): 3 - 3. [Full Text]
|
|